ENLV

Enlivex Therapeutics Ltd

Healthcare Biotechnology

Portfolio

Watchlist

1.27 USD 0.00(0%)

Last update at 2026-11-06T21:00:00Z

VOLUME

18108

Market Cap

15.43M

Momentum Score

…

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range

1.23

Low

1.30

High

52 Week Price Range

0.86

Low

19.80

High

Momentum Score

…

Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

AI Summary

Enlivex Therapeutics Ltd is a clinical-stage biotechnology company developing cell-based immunomodulatory therapies for severe inflammatory and immune-mediated conditions. Long-term growth may be supported by clinical advancement of lead candidates, regulatory progress and commercial adoption in high-unmet-need areas such as sepsis and ARDS. The company could appeal to investors for a differentiated mechanism addressing sizeable acute-care markets.
Key risks include typical clinical-stage biotech exposures: negative trial results or regulatory delays, significant financing and cash‑burn requirements, manufacturing and scale-up challenges, and competition from alternative therapies.

Risk Score

High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close

1.27

Dividend Yield

Revenue TTM

0.00M

Revenue Per Share

Gross Profit TTM

0.00M

Debt / Equity

0.00

ROE

126.17%

Net Debt

-1.37M

ROCE

-0.65%

Diluted EPS TTM

385.30

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	1618.17M	-15.01M	-29.07M	-31.06M	-14.47M
Net income	1235.53M	-15.01M	-29.07M	-42.41M	-9.65M
Selling general administrative	5.68M	4.91M	6.14M	6.70M	6.24M
Selling and marketing expenses	-	-	6.10M	-	-
Gross profit	-0.33M	-0.55M	-0.83M	-	-
Reconciled depreciation	0.33M	0.55M	0.86M	0.78M	0.55M
Ebit	-15.00M	-15.01M	-29.05M	-25.80M	-19.29M
Ebitda	-14.67M	-14.47M	-28.22M	-18.94M	-23.77M
Depreciation and amortization	0.33M	0.55M	0.83M	6.86M	-4.48M
Operating income	-15.00M	-15.54M	-29.39M	-25.80M	-19.29M
Other operating expenses	15.00M	15.54M	29.39M	25.80M	19.29M
Interest expense	0.01M	0.01M	0.01M	5.26M	4.82M
Tax provision	382.65M	0.00M	0.00M	-	-
Interest income	0.79M	1.07M	1.56M	0.83M	0.12M
Net interest income	0.78M	1.06M	1.55M	0.82M	-0.21M
Income tax expense	382.65M	-	4.24M	11.35M	-4.82M
Total revenue	0.00M	0.00M	0.00M	0.00M	0.00M
Total operating expenses	14.67M	14.99M	29.39M	25.80M	19.29M
Cost of revenue	0.33M	0.55M	0.83M	-	-
Total other income expense net	1633.17M	0.52M	0.33M	-5.26M	4.82M
Net income from continuing ops	1235.53M	-15.01M	-27.16M	-31.06M	-14.47M
Net income applicable to common shares	-	-	-	-31.06M	-14.47M

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	2327.00M	27.69M	36.83M	67.64M	95.15M
Intangible assets	582.51M	-	-	-	-
Other current assets	1737.08M	1.08M	6.33M	2.38M	12.32M
Total liab	392.05M	4.10M	6.75M	10.80M	10.11M
Total stockholder equity	1934.95M	23.59M	30.08M	56.84M	85.04M
Other current liab	4.96M	2.75M	4.89M	4.01M	3.22M
Common stock	28.73M	2.69M	2.14M	2.12M	2.11M
Capital stock	28.73M	2.69M	2.14M	2.12M	2.11M
Retained earnings	1108.42M	-127.11M	-112.09M	-83.03M	-51.97M
Other liab	-	-	-	-	5.39M
Other assets	-	-	-	0.41M	6.17M
Cash	2.01M	3.30M	0.93M	47.82M	11.20M
Total current liabilities	9.02M	3.80M	6.06M	6.61M	4.72M
Net debt	-1.37M	-2.77M	0.11M	-42.98M	-10.59M
Short term debt	0.26M	0.23M	0.35M	0.65M	0.62M
Short long term debt total	0.64M	0.53M	1.03M	4.85M	0.62M
Other stockholder equity	796.70M	146.91M	138.94M	136.65M	133.80M
Property plant equipment	-	-	-	14.90M	2.53M
Total current assets	1743.18M	25.99M	33.76M	52.33M	86.44M
Long term investments	-	-	-	-	0.00M
Net tangible assets	-	-	-	56.84M	85.04M
Short term investments	3.86M	20.20M	26.51M	0.30M	72.93M
Net receivables	0.23M	1.30M	0.23M	0.65M	2.20M
Inventory	-	-	-0.23M	1.18M	-12.20M
Accounts payable	3.81M	0.81M	0.83M	1.95M	0.88M
Accumulated other comprehensive income	1.10M	1.10M	1.10M	1.10M	1.10M
Non currrent assets other	582.88M	0.01M	0.18M	0.41M	0.48M
Non current assets total	583.82M	1.69M	3.07M	15.31M	8.70M
Capital lease obligations	0.64M	0.53M	1.03M	0.65M	0.62M

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	-1.26M	9.06M	-32.98M	62.52M	-36.78M
Change to liabilities	-	-	-	1.17M	0.44M
Total cashflows from investing activities	-1.32M	9.06M	-25.97M	62.52M	-38.41M
Total cash from financing activities	10.38M	6.45M	0.36M	0.15M	60.98M
Change to operating activities	-	-	-	-0.36M	-1.80M
Net income	1235.53M	-15.01M	-29.07M	-31.06M	-14.47M
Change in cash	-1.41M	2.50M	-49.13M	38.72M	4.62M
Begin period cash flow	3.41M	1.23M	50.36M	11.64M	7.01M
End period cash flow	2.01M	3.73M	1.23M	50.36M	11.64M
Total cash from operating activities	-10.42M	-13.01M	-23.52M	-23.95M	-17.54M
Issuance of capital stock	10.38M	6.45M	0.36M	0.00M	53.17M
Depreciation	0.33M	0.55M	0.83M	0.78M	0.55M
Other cashflows from investing activities	0.00M	2.29M	0.13M	-	-
Change to account receivables	-3.05M	0.43M	0.61M	-	-
Other cashflows from financing activities	-	-	-25.97M	0.15M	7.81M
Change to netincome	-	-	-	5.53M	-2.26M
Capital expenditures	0.07M	0.10M	0.24M	8.12M	1.62M
Change in working capital	0.81M	-1.22M	-1.82M	0.80M	-1.36M
Stock based compensation	1.78M	2.06M	1.95M	2.71M	2.91M
Other non cash items	-1631.52M	0.61M	4.58M	2.81M	0.41M
Free cash flow	-10.48M	-13.11M	-23.76M	-32.08M	-19.17M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
ENLV Enlivex Therapeutics Ltd	- -%	1.27	-	-	-	0.01	-1.49
NVO Novo Nordisk A/S	0.01 0.02%	40.31	41.58	31.15	2.13	32.99	4.70
VRTX Vertex Pharmaceuticals Inc	4.59 0.85%	547.09	30.22	24.27	10.36	6.50	24.66
REGN Regeneron Pharmaceuticals Inc	1.45 0.16%	904.35	29.07	20.12	7.57	3.82	19.42
ARGNF argenx SE	- -%	900.30	45.77	31.25	13.84	7.12	36.06

Profile*

Enlivex Therapeutics Ltd

Address

14 Einstein Street, Ness Ziona, Israel, 7403618

Contact

972 2 620 8072

Website

https://www.enlivex.com

Employees

Name	Title	Year Born
Mr. Shai Novik M.B.A.	Exec. Chairman	1966
Dr. Oren Hershkovitz Ph.D.	Chief Exec. Officer	1977
Prof. Dror Mevorach M.D.	Founder and Chief Scientific & Medical Officer	1956
Ms. Shachar Shlosberger CPA	Chief Financial Officer	1977
Ms. Sigal Arad	Director of HR	NA
Mr. Veronique Amor-Baroukh	Head Of CMC	NA
Mr. Shai Novik M.B.A.	Executive Chairman	1966
Dr. Oren Hershkovitz Ph.D.	Chief Executive Officer	1977
Mr. Veronique Amor-Baroukh	Senior Director of Operations	NA
Prof. Dror Mevorach M.D.	Founder & Scientific Advisor	1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

Top Gainers*
Top Losers*

Equity Sectors*

Basic Materials

-1.70%
Communication Services

+0.33%
Consumer Cyclical

+0.45%
Consumer Defensive

-0.56%
Energy

-0.25%
Financial Services

+0.49%
Healthcare

+0.20%
Industrials

+0.74%
Real Estate

+1.71%
Technology

-2.81%
Utilities

+0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

TYT	GBX 3102.38 +3.03%
CPG	GBX 33.81 -1.11%
DGED	GBX 93.25 -1.26%
LTOD	GBX 37.75 -1.44%
KNM	GBX 24500.00 +2.04%

DAR	GBX 8.30 +23.42%
VTY	GBX 276.20 +8.23%
GTCO	GBX 0.09 +6.98%
GLV	GBX 2.34 +6.36%
BUR	GBX 249.20 +5.95%

TMI	GBX 0.72 -6.49%
HSBA	GBX 1291.40 -5.42%
RKT	GBX 5218.00 -4.85%
TGA	GBX 643.00 -4.03%
RKH	GBX 61.70 -3.89%